XTX Topco Ltd Has $39,000 Stake in Augmedix, Inc. (NASDAQ:AUGX)

XTX Topco Ltd decreased its position in Augmedix, Inc. (NASDAQ:AUGX) by 48.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 44,245 shares of the company’s stock after selling 41,785 shares during the quarter. XTX Topco Ltd owned 0.09% of Augmedix worth $39,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Augmedix by 16.0% in the 1st quarter. Vanguard Group Inc. now owns 1,302,424 shares of the company’s stock valued at $5,327,000 after purchasing an additional 179,534 shares during the period. Parkman Healthcare Partners LLC raised its stake in shares of Augmedix by 170.1% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,015,814 shares of the company’s stock valued at $5,943,000 after purchasing an additional 639,732 shares during the period. Essex Investment Management Co. LLC raised its stake in shares of Augmedix by 31.1% in the 1st quarter. Essex Investment Management Co. LLC now owns 528,985 shares of the company’s stock valued at $2,164,000 after purchasing an additional 125,457 shares during the period. Hood River Capital Management LLC raised its stake in shares of Augmedix by 79.0% in the 1st quarter. Hood River Capital Management LLC now owns 490,238 shares of the company’s stock valued at $2,005,000 after purchasing an additional 216,339 shares during the period. Finally, Ancora Advisors LLC raised its stake in shares of Augmedix by 102.7% in the 1st quarter. Ancora Advisors LLC now owns 444,660 shares of the company’s stock valued at $1,819,000 after purchasing an additional 225,330 shares during the period. Institutional investors and hedge funds own 87.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Lake Street Capital reissued a “hold” rating on shares of Augmedix in a research note on Monday, July 22nd. William Blair downgraded Augmedix from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Finally, B. Riley downgraded Augmedix from a “strong-buy” rating to a “hold” rating and lowered their target price for the company from $3.00 to $2.35 in a research report on Friday, July 19th. Four investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $3.09.

Augmedix Price Performance

NASDAQ:AUGX opened at $2.35 on Thursday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.66 and a current ratio of 1.66. The stock’s 50-day simple moving average is $2.30 and its 200 day simple moving average is $2.16. The company has a market cap of $115.07 million, a P/E ratio of -5.47 and a beta of -0.22. Augmedix, Inc. has a 52-week low of $0.73 and a 52-week high of $6.25.

Augmedix (NASDAQ:AUGX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $13.66 million for the quarter, compared to analyst estimates of $13.68 million. Augmedix had a negative return on equity of 182.36% and a negative net margin of 46.23%. As a group, sell-side analysts forecast that Augmedix, Inc. will post -0.45 EPS for the current fiscal year.

Augmedix Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.